Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials
Open Access
- 29 April 2020
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 21 (9) , 1015-1025
Abstract
The treatment of rheumatoid arthritis (RA), a chronic, systemic, autoimmune disease, has been greatly advanced by the introduction of biologic disease-modifying antirheumatic drugs (DMARDs); howeve...Keywords
Funding Information
- Astellas Pharma Inc. Astellas Pharma (N/A)
This publication has 55 references indexed in Scilit:
- Janus kinase inhibitors in autoimmune diseasesAnnals of the Rheumatic Diseases, 2013
- Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical considerationJournal of Experimental Medicine, 2013
- In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2012
- Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of CareClinical Therapeutics, 2011
- Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050The Journal of Immunology, 2010
- Methotrexate: the gold standard without standardisationAnnals of the Rheumatic Diseases, 2009
- Janus kinases in immune cell signalingImmunological Reviews, 2009
- Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritisAnnals of the Rheumatic Diseases, 2006
- Therapeutic Strategies for Rheumatoid ArthritisNew England Journal of Medicine, 2004
- Rheumatoid arthritis is a heterogeneous disease: Evidence for differences in the activation of the STAT‐1 pathway between rheumatoid tissuesArthritis & Rheumatism, 2003